On December 22-23, 2021, the U.S. Food and Drug Administration (FDA) announced the emergency use authorization of two oral antiviral medications: Pfizer’s Paxlovid™ (nirmatrelvir/ritonavir) and Merck’s molnupiravir, for the treatment of mild-to-moderate COVID-19.
The FDA’s authorization permits licensed or authorized physicians, advanced practice registered nurses, and physician assistants to prescribe these drugs. Careful utilization review will be required by prescribers and pharmacists to assure appropriate use.
During the Public Health Emergency, the cost of these drugs will be covered by the federal government, and HMAA will pay administrative fees. Therefore HMAA members with prescription coverage will have no out-of-pocket cost during the Public Health Emergency.
HMAA continues to closely monitor developments regarding COVID-19 medication, and we will provide updates as more information becomes available.
Learn more from the U.S. Food and Drug Administration (FDA).